Patents by Inventor Agnes Hamburger

Agnes Hamburger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ADOPTIVE CELL THERAPY FOR TREATMENT OF CANCER ASSOCIATED WITH LOSS OF HETEROZYGOSITY
    Publication number: 20240000938
    Abstract: The disclosure relates to immune cells comprising systems of two engineered receptors each having a ligand binding domain, collectively designed to target cells identified by loss of heterozygosity and used to treat a disease or disorder, for example, cancer. The disclosure provides immune cells expressing two engineered receptors, methods of making same, and polynucleotides and vectors encoding same.
    Type: Application
    Filed: November 23, 2021
    Publication date: January 4, 2024
    Inventors: Carl Alexander Kamb, Agnes Hamburger, Breanna Diandreth, Han Xu, Julyun Oh
  • GENE FUSIONS FOR CONTROL OF GENETICALLY MODIFIED CELLS
    Publication number: 20230330227
    Abstract: The disclosure relates to fusion proteins comprising a tBID polypeptide and a steroid hormone receptor domain, and methods of using same to induce apoptosis in cells.
    Type: Application
    Filed: August 12, 2021
    Publication date: October 19, 2023
    Inventors: Jee Young Mock, Carl Alexander Kamb, Agnes Hamburger
  • COMPOSITIONS AND METHODS FOR TREATING MESOTHELIN POSITIVE CANCERS
    Publication number: 20230277590
    Abstract: The disclosure provides immune cells comprising a first activator receptor specific to mesothelin and a second inhibitory receptor specific to a ligand that has been lost in a mesothelin-positive cancer cell, and methods of making and using same for the treatment of cancer.
    Type: Application
    Filed: December 7, 2022
    Publication date: September 7, 2023
    Inventors: Carl Alexander Kamb, Dora Toledo Warshaviak, Talar Tokatlian, Agnes Hamburger
  • Compositions and methods for treating mesothelin positive cancers
    Patent number: 11602543
    Abstract: The disclosure provides immune cells comprising a first activator receptor specific to mesothelin and a second inhibitory receptor specific to a ligand that has been lost in a mesothelin-positive cancer cell, and methods of making and using same for the treatment of cancer.
    Type: Grant
    Filed: May 10, 2022
    Date of Patent: March 14, 2023
    Assignee: A2 Biotherapeutics, Inc.
    Inventors: Carl Alexander Kamb, Dora Toledo Warshaviak, Talar Tokatlian, Agnes Hamburger
  • ENGINEERED T CELL RECEPTORS AND USES THEREOF
    Publication number: 20220389075
    Abstract: Provided are engineered T-cell receptors comprising fusion proteins comprising a transmembrane domain and an intracellular domain capable of providing a stimulatory signal or an inhibitory signal, and immune cells comprising same.
    Type: Application
    Filed: November 10, 2020
    Publication date: December 8, 2022
    Inventors: Julyun OH, Chang Yi, Dora Toledo Warshaviak, Jee Young Mock, Mark Daris, Agnes Hamburger, James Johnston, Carl Alexander Kamb
  • COMPOSITIONS AND METHODS FOR TREATING MESOTHELIN POSITIVE CANCERS
    Publication number: 20220370497
    Abstract: The disclosure provides immune cells comprising a first activator receptor specific to mesothelin and a second inhibitory receptor specific to a ligand that has been lost in a mesothelin-positive cancer cell, and methods of making and using same for the treatment of cancer.
    Type: Application
    Filed: May 10, 2022
    Publication date: November 24, 2022
    Inventors: Carl Alexander Kamb, Dora Toledo Warshaviak, Talar Tokatlian, Agnes Hamburger
  • COMPOSITIONS AND METHODS FOR TREATING HER2 POSITIVE CANCERS
    Publication number: 20220339194
    Abstract: The disclosure relates to immune cells comprising a dual receptor system responsive to loss of heterozygosity in a target cell, and methods of making and using same. The first receptor comprises activator receptor specific to a HER2 antigen, and the second receptor comprises an inhibitory receptor specific to an antigen lost in cancer but not wild type cells, that inhibits activation of the immune cells by the first receptor.
    Type: Application
    Filed: June 28, 2022
    Publication date: October 27, 2022
    Inventors: Yuta Ando, Agnes Hamburger, Jee Young Mock, Julyun OH, Han Xu, Carl Alexander Kamb